These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19762784)

  • 21. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.
    Sun XM; Eden ER; Tosi I; Neuwirth CK; Wile D; Naoumova RP; Soutar AK
    Hum Mol Genet; 2005 May; 14(9):1161-9. PubMed ID: 15772090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
    Kappelle PJ; Lambert G; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):432-5. PubMed ID: 21122860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
    Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
    Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE; Cao G; Careskey HE; Qian YW; Subramaniam DR; Davies J; Conner EM; Konrad RJ
    Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
    Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
    Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel mutations in SAR1B and MTTP genes in Tunisian children with chylomicron retention disease and abetalipoproteinemia.
    Magnolo L; Najah M; Fancello T; Di Leo E; Pinotti E; Brini I; Gueddiche NM; Calandra S; Slimene NM; Tarugi P
    Gene; 2013 Jan; 512(1):28-34. PubMed ID: 23043934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H; Bissonnette S; Saint-Pierre N; Lamantia V; Cyr Y; Chrétien M; Faraj M
    J Clin Lipidol; 2015; 9(5):664-75. PubMed ID: 26350813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ; Lambert G; Dahlbäck B; Nielsen LB; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):492-4. PubMed ID: 21122852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.
    Vilar-Gomez E; Gawrieh S; Liang T; McIntyre AD; Hegele RA; Chalasani N
    J Clin Lipidol; 2021; 15(2):275-291. PubMed ID: 33454241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL.
    Yue P; Isley WL; Harris WS; Rosipal S; Akin CD; Schonfeld G
    Atherosclerosis; 2005 Jan; 178(1):107-13. PubMed ID: 15585207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
    Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA; George PM; Lambert G
    Atherosclerosis; 2008 Feb; 196(2):659-66. PubMed ID: 17765244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.
    Berge KE; Ose L; Leren TP
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1094-100. PubMed ID: 16424354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.
    Lalanne F; Lambert G; Amar MJ; Chétiveaux M; Zaïr Y; Jarnoux AL; Ouguerram K; Friburg J; Seidah NG; Brewer HB; Krempf M; Costet P
    J Lipid Res; 2005 Jun; 46(6):1312-9. PubMed ID: 15741654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
    Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
    Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four novel mutations in APOB causing heterozygous and homozygous familial hypobetalipoproteinemia.
    Whitfield AJ; Marais AD; Robertson K; Barrett PH; van Bockxmeer FM; Burnett JR
    Hum Mutat; 2003 Aug; 22(2):178. PubMed ID: 12872264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
    Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
    Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
    Brouwers MC; van Greevenbroek MM; Troutt JS; Bonner Freeman A; Lu A; Schaper NC; Konrad RJ; Stehouwer CD
    Clin Sci (Lond); 2011 Nov; 121(9):397-403. PubMed ID: 21539517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial hypobetalipoproteinemia: analysis of three Spanish cases with two new mutations in the APOB gene.
    Martín-Morales R; García-Díaz JD; Tarugi P; González-Santos P; Saavedra-Vallejo P; Magnolo L; Mesa-Latorre JM; di Leo E; Valdivielso P
    Gene; 2013 Nov; 531(1):92-6. PubMed ID: 24001780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.